ClinicalTrials.Veeva
Menu

Find clinical trials for Multiple Myeloma in Phoenix, AZ

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Plasma Cell Cancer
Recurrence
Cancer
Hematologic Cancer
Lymphoma
Non-Hodgkin Lymphoma
Leukemia

Multiple Myeloma trials near Phoenix, AZ, USA:

Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM) (KarMMa-3)

versus standard regimens in subjects with relapsed and refractory multiple myeloma (RRMM).The study is anticipated to randomize app...

Active, not recruiting
Multiple Myeloma
Biological: bb2121
Drug: Dexamethasone

Phase 3

Celgene
Celgene

Scottsdale, Arizona, United States and 59 other locations

phases, for the treatment of patients with relapsed/refractory multiple myeloma (RRMM) and newly diagnosed multiple myeloma...

Enrolling
Multiple Myeloma
Drug: Selinexor
Drug: Mezigdomide

Phase 1, Phase 2

Karyopharm Therapeutics
Karyopharm Therapeutics

Gilbert, Arizona, United States and 25 other locations

Open-Label, Study to Investigate the Safety and Efficacy of CLN-619 (anti-MICA/MICB Antibody) in Patients with Relapsed and Refractory Multiple...

Active, not recruiting
Multiple Myeloma
Drug: CLN-619

Phase 1

Cullinan Therapeutics Inc.

Phoenix, Arizona, United States and 7 other locations

1b/2, open label, multi-center, Clinical Study of Chimeric Antigen Receptor T Cells targeting BCMA in patients with relapsed and or refractory multiple...

Active, not recruiting
Multiple Myeloma
Biological: zevor-cel

Phase 1, Phase 2

CARsgen Therapeutics

Phoenix, Arizona, United States and 12 other locations

a phase 1b/2, open-label, multicenter study of GC012F (AZD0120), a CD19/BCMA dual CART-cell therapy, in adult subjects with relapsed/refractory Multiple...

Enrolling
Relapsed/ Refractory Multiple Myeloma
Biological: GC012F (AZD0120)

Phase 1, Phase 2

AstraZeneca
AstraZeneca

Phoenix, Arizona, United States and 35 other locations

interventional, modular, open-label, multicenter study to primarily evaluate the safety and tolerability of AZD0120 in adult participants with multiple...

Enrolling
Multiple Myeloma
Biological: AZD0120

Phase 1

AstraZeneca
AstraZeneca

Phoenix, Arizona, United States and 12 other locations

Multiple myeloma (MM) is a cancer of the blood's plasma cells. The cancer is typically found in the bones and bone marrow (the spon...

Enrolling
Multiple Myeloma
Drug: Intravenous (IV) Etentamig
Drug: Subcutaneous (SC) Etentamig

Phase 1

AbbVie
AbbVie

Phoenix, Arizona, United States and 14 other locations

determine the Recommended Phase 2 Dose and clinical benefit of elranatamab in combination with other anti-cancer therapies in participants with multiple...

Active, not recruiting
Multiple Myeloma
Drug: Elranatamab + lenalidomide + dexamethasone
Drug: Elranatamab + Nirogacestat

Phase 2

Pfizer
Pfizer

Phoenix, Arizona, United States and 24 other locations

Multiple Myeloma (MM) is a cancer of the blood's plasma cells ( blood cell). The cancer is typically found in the bones and bone ma...

Enrolling
Multiple Myeloma
Drug: Etentamig (ABBV-383)

Phase 1

AbbVie
AbbVie

Phoenix, Arizona, United States and 40 other locations

with Relapsed/Refractory (r/r) Non-Hodgkin's Lymphoma (NHL) or Multiple Myeloma (MM). Cemsidomide may be administered as a single a...

Active, not recruiting
Multiple Myeloma
Lymphoma, Non-Hodgkin's
Drug: Dexamethasone Oral
Drug: cemsidomide

Phase 1

C4 Therapeutics

Phoenix, Arizona, United States and 12 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems